average weight loss on retatrutide trial data New Phase 3 just dropped 👀 Eli Lilly's reported approaching retatrutide weight loss phase 2

Personalized Peptide Research: The future may involve tailoring peptide stacks based on specific cellular profiles or genetic markers, allowing for highly targeted and individualized research protocols

Sources Jiang Y, et al

This drug may cause side effects, including but not limited to nausea, diarrhea, dry mouth, headaches, decreased appetite, sexual problems

Summary: The dosing schedule for retatrutide used in Phase 2 clinical trials involved once-weekly subcutaneous injections starting at a low dose and gradually escalating up to 12 mg, but retatrutide is not yet approved for use in the UK

doi:10.1038/s41598-019-51374-8 Makedonov I, Kahn SR, Galanaud JP